Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

BioSpace
biospace.com > press-releases > puma-biotechnology-to-host-conference-call-to-discuss-second-quarter-2026-financial-results

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

1+ day, 15+ hour ago   (193+ words) Statistics cookies help us to understand how visitors interact with websites by collecting and reporting information anonymously. Marketing cookies allow us to display more relevant ads that are engaging for our users and thereby, they are more valuable for publishers…...

Google News
biospace.com > press-releases > jubilant-biosys-brings-together-global-biotech-leaders-to-advance-the-future-of-healthcare-innovation-at-2nd-edge-innovation-forum

Jubilant Biosys Brings Together Global Biotech Leaders to Advance the Future of Healthcare Innovation at 2nd EDGE Innovation Forum

1+ day, 17+ hour ago   (480+ words) BioSpace Jubilant Biosys Brings Together Global Biotech Leaders to Advance the Future of Healthcare Innovation at 2nd EDGE Innovation Forum - Over 50 organizations represented, including 40 biotechnology companies - More than 5 large pharmaceutical companies and 8 investment firms represented - Representatives from 8 companies participated in 2 on-stage…...

BioSpace
biospace.com > press-releases > sensient-technologies-corporation-reports-results-for-the-quarter-ended-june-30-2026

Sensient Technologies Corporation Reports Results for the Quarter Ended June 30, 2026

1+ day, 13+ hour ago   (226+ words) MILWAUKEE--(BUSINESS WIRE)--Sensient Technologies Corporation (NYSE: SXT), a leading provider of flavors and colors for the food, pharmaceutical, and personal care markets, today reported financial results for the second quarter ended June 30, 2026. Second Quarter Group Results The Flavors & Extracts…...

Google News
biospace.com > press-releases > thermo-fisher-scientific-launches-thermo-scientific-instaflux-to-help-food-microbiology-labs-simplify-workflows-in-pathogen-and-environmental-testing

Thermo Fisher Scientific Launches Thermo Scientific™ InstaFlux™ to Help Food Microbiology Labs Simplify Workflows in Pathogen and Environmental Testing

1+ day, 16+ hour ago   (181+ words) Laboratories interested in learning more about Thermo Scientific InstaFlux or requesting a demonstration should contact their Thermo Fisher representative, visit www.thermofisher.com/instaflux or visit booth 200 at the upcoming International Association for Food Protection (IAFP) Conference from July 26 – 29, 2026. Who…...

BioSpace
biospace.com > press-releases > almirall-h1-2026-results

Almirall H1 2026 Results

1+ day, 14+ hour ago   (380+ words) Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business – reiterating guidance aligned with long-term growth trajectory Results were led by the continued growth of the European Dermatology business, which increased 18.1% YoY…...

Google News
biospace.com > press-releases > harbour-biomed-announces-positive-profit-alert-for-2026-interim-results-marking-seventh-consecutive-profitable-half-year-as-platform-based-advantages-drive-sustainable-growth

Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

1+ day, 15+ hour ago   (261+ words) CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for…...

BioSpace
biospace.com > press-releases > par-health-launches-first-and-only-generic-version-of-janumet-xr-sitagliptin-and-metformin-hcl-extended-release-tablets-in-the-united-states

Par Health Launches First and Only Generic Version of Janumet® XR (sitagliptin and metformin HCl extended-release) Tablets in the United States

1+ day, 13+ hour ago   (470+ words) BioSpace Par Health Launches First and Only Generic Version of Janumet® XR (sitagliptin and metformin HCl extended-release) Tablets in the United States First-to-Market Generic Entry Underscores Par Health's Commitment to Expanding Access to High-Quality, Affordable Medicines ST. LOUIS, July 24, 2026 /PRNewswire…...

BioSpace
biospace.com > press-releases > vir-biotechnology-announces-chief-financial-officer-transition

Vir Biotechnology Announces Chief Financial Officer Transition

1+ day, 14+ hour ago   (341+ words) BioSpace Vir Biotechnology Announces Chief Financial Officer Transition SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne…...

BioSpace
biospace.com > press-releases > estrella-immunopharma-announces-first-patient-dosed-in-dose-expansion-phase-of-starlight-1-trial-and-reports-durable-response-rate-in-advanced-b-cell-non-hodgkins-lymphoma

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma

1+ day, 11+ hour ago   (531+ words) BioSpace Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company…...

BioSpace
biospace.com > press-releases > gsks-shingrix-recombinant-zoster-vaccine-prefilled-syringe-presentation-approved-in-canada

GSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Canada

1+ day, 12+ hour ago   (370+ words) MISSISSAUGA, ON, July 24, 2026 /CNW/ -- GSK Canada today announced the approval of Shingrix (GSK's Recombinant Zoster Vaccine or RZV) in a prefilled syringe. This new presentation removes the need to reconstitute separate vials prior to administration, simplifying the vaccine administration process…...